AMPH抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 60 μg, Lane: Mouse lung tissue, Primary antibody: P07074(AMPH Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P07074(AMPH Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07074(AMPH Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

AMPH antibodies target amphiphysin, a protein primarily involved in synaptic vesicle endocytosis within nerve terminals. Discovered in the 1990s, amphiphysin plays a critical role in clathrin-mediated membrane recycling, facilitating neurotransmitter release. Its association with autoimmunity emerged when AMPH antibodies were linked to paraneoplastic neurological syndromes (PNS), particularly stiff-person syndrome (SPS) and encephalomyelitis. These antibodies are often detected in patients with underlying malignancies, most commonly breast and lung cancers, where they arise due to cross-reactivity between tumor antigens and neuronal proteins.

AMPH antibodies are IgG-type autoantibodies that disrupt synaptic function by interfering with amphiphysin’s interaction with other endocytic proteins, such as dynamin and clathrin. This disruption impairs vesicle recycling, leading to neurological symptoms like muscle rigidity, spasms, and autonomic dysfunction. Diagnostic testing typically involves serum or cerebrospinal fluid (CSF) analysis using techniques like immunohistochemistry, cell-based assays, or Western blot. Early detection is crucial, as AMPH antibody-related PNS often precedes cancer diagnosis, guiding oncological screening.

Research continues to explore amphiphysin’s broader roles in neurobiology and its potential as a biomarker for both neurological autoimmunity and cancer. Immunotherapy, including intravenous immunoglobulins or plasmapheresis, may alleviate symptoms, though cancer treatment remains central to managing paraneoplastic cases.